A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

Drew W. Rasco,Nehal J. Lakhani,Yufeng Li,Lichuang Men,Hengbang Wang,Jiao Ji,Yuefen Tang,Zhiyan Liang,Alex Amaya,Kathy Estkowski,Joan Sun,Yingjie Huang,Dajun Yang,Yifan Zhai

A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors.

2019

Drew W. Rasco
Nehal J. Lakhani
Yufeng Li
Lichuang Men
Hengbang Wang
Jiao Ji
Yuefen Tang
Zhiyan Liang
Alex Amaya
Kathy Estkowski
Joan Sun
Yingjie Huang
Dajun Yang
Yifan Zhai

3126Background: APG-115 is a potent and orally active small-molecule MDM2 protein inhibitor. Binding to MDM2 protein, APG-115 restores p53 tumor suppressive function via induction of apoptosis in t...

Keywords:

Antagonist
Pathology
Oncology
Mdm2
Internal medicine
Medicine
Apoptosis
Mdm2 Protein
in patient
Pharmacology
phase i study
orally active

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations